Camostat mesylate has been approved for repurposing in treating patients infected with the SARS-Cov-2 virus.
Even though there is no approved therapy for COVID-19, studies have demonstrated that Camostat Mesylate can prevent the entry of the SARS-Cov-2's cellular entry into a human host, thus preventing the virus from multiplying itself in the human system.
The drug camostat mesylate is used in countries like Japan and South Korea in the treatment of Chronic pancreatitis. In the wake of the COVID-19 crisis, the University of Tokyo among others has announced plans to repurpose this drug into clinical trials to treat patients suffering from the SARS-Cov-2 infection.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.